As soon as the 10x Bull Stock Andon Health Co.Ltd(002432) received the attention letter, it announced the landing of 2.1 billion U.S. large orders. Today, the share price rose again.
10 times bull stocks rose by the word limit again
On January 13, Andon Health Co.Ltd(002432) opened with a word limit, and the share price rose 10% to 68.44 yuan / share. It walked out of the three connected boards and hit a new high. The current market value is 32.8 billion yuan. As of the midday closing, the stock still had more than 65000 orders on the trading board.
Andon Health Co.Ltd(002432) is a big bull stock tested by covid-19. Since November 12 last year, the company’s share price has soared one after another. Today is the company’s 26th daily limit in nearly two months.
With this limit, the share price of Andon Health Co.Ltd(002432) rose from the starting point near 7 yuan to 68 yuan in two months, with a cumulative increase of more than 9 times.
It is worth noting that since the low point in early November 2011, the stock has increased by more than 10 times, and the total market value has increased by more than 30 billion yuan.
According to public information, Andon Health Co.Ltd(002432) is mainly engaged in the R & D, production and sales of household medical devices, and its main products are electronic sphygmomanometers, blood glucose meters and other electronic medical devices.
The company once introduced that the company’s overseas business mainly includes OEM production (ODM / OEM) for foreign manufacturers and overseas sales of ihealth brand and edevice products. Among them, the ihealth brand product model is sold by the company to overseas subsidiaries, and then overseas subsidiaries are responsible for overseas sales.
obtained overseas large orders of more than 2 billion yuan
On January 12, Andon Health Co.Ltd(002432) rose again, and its share price hit a record high, with a total market value of 29.8 billion yuan. After the closing, Andon Health Co.Ltd(002432) released major good news. This good news is also the direct reason for the word limit of the company’s stock today.
Yesterday, Andon Health Co.Ltd(002432) announced that the order for ihealth covid-19 antigen home self-test OTC kit received by the U.S. subsidiary from New York and Massachusetts was effective on the day of receipt of the order (local time); The sales contract of ihealth kit signed with the Department of health of New York state of the United States shall enter into force on January 10, 2022 local time.
The announcement pointed out that the U.S. subsidiary received two purchase orders for ihealth test kits from the New York State Department of health and the New York State non-profit organization health research incorporated on December 21, 2021 local time, The order amount is US $25.08 million (including freight) and US $40.23 million (including freight), respectively. The total order amount is US $65.31 million (including freight), about 415 million yuan.
In addition, the U.S. subsidiary and the New York State Department of health signed a sales contract on January 10, 2022 local time to sell ihealth kit products to the New York State Department of health. The total contract price tax is 120 million US dollars (including freight), about 763 million yuan.
As of the announcement date, the cumulative amount of orders and contracts between the U.S. subsidiary and the New York State Department of health was US $185 million, about RMB 1.179 billion, exceeding 50% of the company’s audited main business revenue in 2020 (RMB 1.004 billion).
Meanwhile, the U.S. subsidiary obtained the purchase order from the Executive Office of the federal and Department of health and human services of Massachusetts from December 3, 2021 to January 5, 2022 local time. The U.S. subsidiary of the company sold ihealth kits to the Executive Office of the federal and Department of health and human services of Massachusetts, The total amount of contract price tax is 148 million US dollars (including freight), about 944 million yuan.
The company said that the performance of orders and contracts will have a positive impact on the company’s operating revenue and operating profit in 2021 and 2022. With the fulfillment of orders and contracts, it will help to strengthen mutual trust and further cooperation between both parties, expand the brand popularity of the company and its U.S. subsidiaries in the United States, and strive for more customer resources and orders.
At the same time, the company once again reminded investors of the risk that some orders and contracts may not be performed on time or in full due to the impact of local epidemic situation changes, policy changes, supply chain capacity changes, logistics and transportation risks, unpredictable or force majeure and other factors during the execution of orders and contracts.
the strongest king of covid-19 detection concept
Behind the soaring share price is that on November 8 this year, Andon Health Co.Ltd(002432) announced that the covid-19 self-test kit developed by its U.S. subsidiary ihealth was approved for use in the United States. U.S. residents can buy and use it through e-commerce platforms, pharmacies, supermarkets and other channels without prescription.
The instructions for using the kit on Amazon show that the kit is mainly used for rapid and qualitative detection of viruses in human anterior nasal swab samples in vitro. It can be collected and operated by individuals, and the test results can be displayed in 15 minutes.
From about November 15, Andon Health Co.Ltd(002432) began to disclose when replying to investors on the interactive platform that “the market demand is on the rise”, “the kit has been sold locally to both end C and end B”, “the kit products belong to the product category intensively purchased by the U.S. federal government”, “the kit has started mass production and sold well in local spot”, “the current monthly production capacity is 100 million people” “It is estimated that by the beginning of 2022, the production capacity will increase by 200 million people per month”.
After the announcement, since the fermentation of the news on November 15, Andon Health Co.Ltd(002432) share price has made rapid progress, from 6.9 yuan per share opened on the 15th to 39.52 yuan per share closed on the 24th, an increase of 472.75%.
received several attention letters from Shenzhen Stock Exchange
In the past two months, with the sharp rise of the company’s share price, the exchange has sent letters to Andon Health Co.Ltd(002432) many times, but neither the attention letter nor the supervision letter can hold down the rising K-line of Andon Health Co.Ltd(002432) .
Just before the company announced the favorable order last night, Andon Health Co.Ltd(002432) just received a letter of concern from the Shenzhen Stock Exchange, asking Andon Health Co.Ltd(002432) to explain whether the disclosure is cautious and objective, and whether there are exaggerated publicity and misleading tips to cater to the hot concept of the market and hype the stock price. This concern letter is the fourth one the company has received since November last year.
Except for the equity incentive for Andon Health Co.Ltd(002432) for the first time, the rest are all around the OTC kit. It is worth mentioning that each time it is related to the reply of Andon Health Co.Ltd(002432) on the interactive platform for investors.
On November 8, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary ihealth covid-19 test kit was approved by the FDA for emergency use. Later, when answering investors\’ questions on the interactive easy platform, it made responses such as “market demand is on the rise” and “the kit has started mass production and sold well in local spot”.
Since the disclosure of the information on November 8, as of the closing of November 23, the company’s share price has increased by 121.17% for seven consecutive trading days.
In this regard, the Shenzhen Stock Exchange issued a concern letter for the second time, asking the company to explain a series of replies on the interactive trading platform after the disclosure, explain the relationship between this behavior and the previous two share buybacks, and answer whether the company is suspected of raising the share price, so as to facilitate the incentive objects of the 2020 stock option incentive plan to exercise their rights independently to make profits.
On November 24, the Shenzhen Stock Exchange again issued a letter of concern, asking the company to explain whether there was any violation of the accuracy, timeliness and fairness of information disclosure, and whether there was any use of the interactive platform to cater to market hot spots and hype the company’s share price.
However, after receiving the letter of concern, the share price of Kowloon medical was not affected, but continued to rise by 9.9% on the same day.
Andon Health Co.Ltd(002432) also received the exchange supervision letter. On the evening of December 14, Andon Health Co.Ltd(002432) received the supervision letter from Shenzhen Stock Exchange. The main problem was that the reply of listed companies on the interactive platform on the progress of obtaining the authorization of FDA EUA for the kit was earlier than that disclosed in the designated media.
deduction of non net profit in the first three quarters of last year
In terms of performance, according to the financial report data, the net profits of Andon Health Co.Ltd(002432) from 2017 to 2019 were -166 million yuan, 12.6868 million yuan and 66.4491 million yuan respectively. Affected by the epidemic, the global demand for epidemic prevention products surged in 2020, which greatly increased Andon Health Co.Ltd(002432) net profit by 264.68% year-on-year to 242 million yuan.
But since last year, Andon Health Co.Ltd(002432) sales of forehead thermometers have begun to decline. According to the third quarterly report, Andon Health Co.Ltd(002432) the net profit in the first three quarters was 50.12 million yuan, a year-on-year decrease of 86.19%, and a loss of 24.775 million yuan after deduction.
With the spread of Omicron, the demand for home self inspection products in the United States has surged. At present, Omicron has become the main epidemic strain in the United States, and the infection cases of Omicron account for 73%.
Many media reported that covid-19 testing sites in the United States have lined up, and some pharmacies have sold out of household testing reagents.
Some of Amazon’s household testing products are also out of stock. However, covid-19 self-test products are not the exclusive products of Andon Health Co.Ltd(002432) . According to incomplete statistics, Daan Gene Co.Ltd(002030) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing Hotgen Biotech Co.Ltd(688068) and other more than ten domestic enterprises have approved relevant products and sold them to overseas markets. Among them, Beijing Hotgen Biotech Co.Ltd(688068) also due to the hot sales of self-test products in Europe, the net profit increased by more than 700 times in the first half of the year.
